You just read:

Janssen Submits Application to U.S. FDA Seeking Approval of DARZALEX® (daratumumab) Combination Therapy for Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant Ineligible

News provided by

Janssen Pharmaceutical Companies of Johnson & Johnson

Mar 12, 2019, 16:30 ET